3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Classical hematology
1
Conditions
Tourette Syndrome
1
Stress Disorders, Post-Traumatic
1
Sleep Initiation and Maintenance Disorders
1
Severe Acute Respiratory Syndrome
1
Seizures
1
Parkinson Disease
1
Opioid-Related Disorders
1
Neoplasms
1
Multiple Sclerosis
1
Inflammatory Bowel Diseases
1
Hepatitis C
1
Glaucoma
1
Fibromyalgia
1
Epilepsy
1
Depression
1
Crohn Disease
1
Coronavirus Infections
1
Colitis, Ulcerative
1
Chronic Traumatic Encephalopathy
1
Chronic Pain
1
COVID-19
1
Brain Injuries, Traumatic
1
Bipolar Disorder
1
Autistic Disorder
1
Anxiety Disorders
1
Anemia, Sickle Cell
1
Amyotrophic Lateral Sclerosis
1
Acquired Immunodeficiency Syndrome
1
Interventions
avatrombopag
5
iron isomaltoside 1000
4
hetrombopag
3
ferric carboxymaltose
3
Cytarabine
3
eltrombopag
2
Rivaroxaban
2
Radiotherapy
2
Meropenem
2
Idarubicin
2
Granulocyte Colony-Stimulating Factor
2
Etoposide
2
Erythropoietin
2
Cyclophosphamide
2
Azacitidine
2
thymoglobulin
1
stinging nettle lectin
1
romiplostim
1
raltitrexed
1
peppermint oil
1
pegfilgrastim
1
oprelvekin
1
fludarabine phosphate
1
fludarabine
1
ferrous succinate
1
ferrous fumarate
1
ferric derisomaltose
1
epoetin beta
1
cc-486
1
Vitamin B 12
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Medical Marijuana
×
Classical hematology
×
Clear all
NCT03944447
2022-06-02
OMNI-Can
OMNI Medical Services, LLC
Phase 2
Unknown
200,000 enrolled